Labigat (Ranolazine)

Ranolazine blocks the late inward sodium current in heart muscle cells, decreasing intracellular sodium and secondary calcium overload. This action improves myocardial relaxation and coronary blood flow without markedly changing heart rate or blood pressure, thereby relieving angina symptoms.

The specific dose of Labigat is determined by the prescribing physician based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for ranolazine in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Labigat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with beta‑blockers or calcium‑channel blockers, ranolazine does not significantly affect heart rate or blood pressure, making it useful as add‑on therapy. Its unique mechanism targeting the late sodium current offers symptom relief for patients who remain symptomatic despite conventional antianginal agents.

Labigat should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

Labigat is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless otherwise instructed.

The most serious risks include QT interval prolongation, which can lead to ventricular arrhythmias, severe hepatic dysfunction, and rare hypersensitivity reactions such as angioedema or anaphylaxis. Patients should be monitored for these events, especially when taking other QT‑prolonging drugs.

Labigat is contraindicated in patients with known prolonged QT syndrome, severe hepatic impairment, or those taking strong CYP3A4 inhibitors without dose adjustment. It should also be avoided in individuals with a history of serious hypersensitivity to ranolazine or any of its excipients.